洛鉬(03993.HK):巴西磷尾礦再利用項目試產 料全年交付10.5萬噸精礦
洛陽鉬業(03993.HK)公佈,旗下洛鉬巴西以生物技術對磷選礦尾礦進行再利用的項目於4月實現試生產,目前低含量磷灰石精礦已開始正式銷售,預期到全年將交付10.5萬噸低含量磷灰石精礦,至年底可增加收入約520萬美元。
公司透露,該項目是由洛鉬巴西與IFB集團攜手完成,於2020年正式啓動,由IFB集團負責投資230萬美元,並由洛鉬提供技術人員和尾礦及研究開發場所,預料有助滿足巴西對磷肥的需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.